2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5868 Spatial multiplex imaging of tumor microenvironment to predict CAR T cell therapy outcome in diffuse large B-cell lymphoma

Jia-Jye Lee, PhD, Rahil Eftekhari, PhD2, Charles Yin, MD, PhD3, David Scheiblin, PhD4, Alun Carter, PhD, BSc5, Michael Chu, MD, FRCPC6, Rimas Orentas, PhD7
1 Miltenyi Biotec, Gaithersburg, Maryland, United States
2 University of Alberta, Edmonton, Canada
3 University of Alberta, Edmonton, Canada
4 Miltenyi Biotec, Gaithersburg, Maryland, United States
5 Miltenyi Biotec, Gaithersburg, Maryland, United States
6 University of Alberta, Edmonton, Canada
7 Miltenyi Biotec, Gaithersburg, Maryland, United States

Background

We investigated pre-and post-treatment tissue samples from patients receiving a unique anti-CD19 CAR, featuring a TNFRSF19 transmembrane domain and 4-1BB/CD3ζ signaling domains enrolled in the ACIT001/EXC002 trial, with documented CD19+ non-Hodgkin lymphoma (Clinicaltrials.gov: NCT03938987, PI: Dr. M.P. Chu). Multiplex immunofluorescence imaging enables simultaneous detection of protein and RNA biomarkers and spatial characterization of the tumor microenvironment (TME) and cellular neighborhoods. We characterized the immune and TME landscape of tissue biopsies to identify disease-associated immune features associated with CAR T cell therapy responsiveness and durable remission.

Methods

The MACSima™ imaging cycling staining system was used to acquire sequential antibody-based staining of 57 stromal, immune, and lymphoma cells markers. We tested 16 formalin-fixed paraffin-embedded (FFPE) tissue sections from 12 patient DLBCL biopsies (12 pre- and 4 post- CAR T cell therapy). The cohort included de-identified samples from non-responders, partial responders with subsequent relapse, and responders who achieved a durable response (> 24 months). TME and immune contexts were analyzed by multiplex imaging with cell segmentation, unsupervised clustering and cell frequency analysis.

Results

Distinct spatial immune compositions were identified among three representative groups. Notably, the presence of distinct T cell clusters within the TME was associated with a favorable initial response to CAR T cell therapy. Responders showed increased memory T cell infiltration, including CD3+CD4+CD45RO+ helper T cells (10.2 ± 5.4% vs. 1.1 ± 0.5%) and CD3+CD8+CD45RO+ cytotoxic T cells (5.3 ± 5.6% vs. 0.8 ± 0.9%), compared with non-responders. A two-fold difference was observed between helper and cytotoxic T lymphocyte populations in responders. Interestingly, responders had higher infiltration of CD3+CD4+PD-1+ T cells than non-responders (6.5 ± 4.7% vs. 0.8 ± 0.4%) with a similar trend observed for CD3+CD8a+PD-1+ cells.

Spatial analyses revealed heterogenous myeloid populations and T cell-myeloid interactions within the TME. Responders had a higher amount of antigen-presenting myeloid cells, including CD11c+CD68+ M1 macrophages (5.5 ± 4.6% vs. 0.7 ± 0.4%) and CD11c+CD68- dendritic cells (10.3 ± 5.0% vs. 1.7 ± 0.6%), compared with partial responders. In contrast, M2 macrophages (CD163+ or CD206+) were present in all biopsies but varied substantially in abundance.

We integrated these findings into a scoring system based on immunosuppressive TME features, including: T-cell lineage and exhaustion markers (CD3, CD4, CD8a, CD45RO, PD-1, CTLA-4, and FoxP3) and macrophage subtype markers (CD11b, CD11c, CD14, CD16, CD68, CD163, and CD206).

Early after CAR T infusion, the lymphoma biopsies exhibited dynamic interactions between CAR T cells and the TME. Spatial heterogeneity was clear upon H&E staining and subsequent definition of tumor-rich (CD20+ and PAX5+), muscle (demsin+), necrotic, immune-rich and immune-evasive regions. In a partial responder biopsy, we observed CD19 antigen loss in lymphoma cells adjacent to infiltrating CAR T cells, while CD20 and PAX5 expression was retained. Elevated PD-L1 expression on neighboring monocytes and macrophages was also observed, suggesting concurrent mechanisms of antigen escape and immunosuppression.

Conclusions

Multiplex imaging revealed that the lymphoma microenvironment provides insights into potential therapeutic responses to CAR T cell therapy. Intra-tumoral dense T-cell clusters with a PD1(+) and CD45RO(+) phenotype in DLBCL were noted prior to CAR-T infusion. Strikingly, spatial niches of these pre-existing memory T cells were a key feature that correlated with an initial response to CAR T cell therapy. This may suggest that CAR T cells derived from pre-existing memory T cell populations, together with a “hot” TME featuring immune infiltration and chemokine responses, may be associated with enhanced persistence and improved clinical outcomes. Despite a limited sample size, we demonstrate that treatment durability may be limited by both antigen escape and an immunosuppressive tumor microenvironment driven by tumor-immune and immune-immune cell interactions.

Jia-Jye Lee, PhD: Miltenyi Biotec - Current Employment